Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India

被引:2
|
作者
Taneja, Juhi [1 ,7 ]
Chatterjee, Kuhu [1 ]
Sasidharan, Jaseetha [2 ]
Abbas, Syed Zafar [3 ]
Rai, Anil Kumar [2 ]
Raychaudhury, Sujata [4 ]
Das, Bhabatosh [5 ]
Das, Asim [6 ]
机构
[1] ESIC Med Coll & Hosp, Dept Microbiol, Faridabad, India
[2] ESIC Med Coll & Hosp, Dept ENT, Faridabad, India
[3] ESIC Med Coll & Hosp, Dept Radiol, Faridabad, India
[4] ESIC Med Coll & Hosp, Dept Pathol, Faridabad, India
[5] Translat Hlth Sci & Technol Inst, Faridabad, India
[6] ESIC Med Coll & Hosp, Faridabad, India
[7] ESIC Med Coll & Hosp, Dept Microbiol, Faridabad 121001, Haryana, India
关键词
mucormycosis; COVID-19-associated mucormycosis; rhino-orbito-cerebral mucormycosis; antifungal susceptibility; amphotericin B; MANAGEMENT; MUCOR;
D O I
10.1093/mmy/myad067
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The second wave of coronavirus disease 2019 (COVID-19), during the early 2021, lead to a devastating outbreak of mucormycosis in India. This study aimed to determine the aetiology, clinical features, comorbidities, and risk factors of rhino-orbito-cerebral mucormycosis (ROCM) and antifungal susceptibility pattern for the isolates. The study included all suspected cases of ROCM in post-COVID-19 patients attending the hospital from May to December 2021. A total of 70 patients were diagnosed with mucormycosis during the study period. The commonest presentations were rhino-orbital and rhino-orbito-cerebral in 35.7% of cases each. Diabetes mellitus was the commonest associated risk factor in 95.7% of all patients, while 78.5% of the patients were treated with corticosteroids in the recent past, and 25.7% presented with active COVID-19 pneumonia. The commonest isolate was Rhizopus arrhizus n = 14, followed by Aspergillus flavus n = 16, A. fumigatus n = 4, A. niger n = 3, Fusarium oxysporumn = 1, and Apophysomyces variabilisn = 1. Fungal species identification was done by phenotypic methods for all the isolates and DNA sequence analysis of 18 isolates, and antifungal susceptibility testing of 30 isolates was performed by commercially prepared HiMIC plate (HiMedia, Mumbai, India) using broth microdilution for amphotericin B, isavuconazole, itraconazole, voriconazole, and posaconazole. The MIC50 and MIC90 of amphotericin B for R. arrhizus strains were 0.25 and 4 & mu;g/ml, respectively; and the MIC50 and MIC90 results for itraconazole, posaconazole, and isavuconazole were 8 and 8, 2 and 2, and 2 and 8 & mu;g/ml, respectively. In vitro data showed that amphotericin B was the most effective antifungal against most species. The commercially available ready-to-use minimum inhibitory concentration plates are user-friendly for performing antifungal susceptibility, which may be useful in choosing appropriate regimens and monitoring emerging resistance.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Rapidly progressing rhino-orbito-cerebral mucormycosis with concomitant pulmonary mucormycosis in a Post-COVID-19 diabetic subject
    Dhawan, Vaishali Bodhraj
    Manoj, Megha
    INDIAN JOURNAL OF PUBLIC HEALTH, 2024, 68 (01) : 137 - 139
  • [2] Rhino-orbito-cerebral mucormycosis in a post-COVID-19 diabetic patient: Rare case from Iran
    Fakhar, Mahdi
    Sharifpour, Ali
    Zakariaei, Zakaria
    Banimostafavi, Elham Sadat
    Soleymani, Mostafa
    Davoodi, Lotfollah
    CLINICAL CASE REPORTS, 2022, 10 (02):
  • [3] Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control
    Mitra, Sandipta
    Janweja, Mridul
    Sengupta, Arunabha
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2021, 279 (5) : 2417 - 2422
  • [4] Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control
    Sandipta Mitra
    Mridul Janweja
    Arunabha Sengupta
    European Archives of Oto-Rhino-Laryngology, 2022, 279 : 2417 - 2422
  • [5] Pulmonary rehabilitation in the management of rhino-orbito-cerebral mucormycosis infection: A post-covid-19 complication
    Daga, Shrushti
    Yadav, Vaishnavi
    Warutkar, Vaishnavi
    Saifee, Sakina
    Jain, Moli Jai
    MEDICAL SCIENCE, 2022, 26 (128)
  • [6] Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
    Ramamurthy, Lakshmi B.
    Bhandari, Ridhi
    Kanakpur, Savitha
    Thejaswini, P.
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (03) : 1019 - 1024
  • [7] Mortality and its determinants after an outbreak of post COVID-19 associated rhino-orbito-cerebral mucormycosis in Central India
    Nagarkar, Nitin M.
    Sahu, Vijaya
    Arora, Ripudaman
    Pathak, Madhumallika
    Shambharkar, Martina S.
    Naveen, Prithvi
    INTERNATIONAL OPHTHALMOLOGY, 2023, 43 (07) : 2363 - 2370
  • [8] Case series of post-COVID-19 rhino-orbito cerebral mucormycosis in Egypt
    Elmonofy, Omar
    Richardson, Sunil
    Mubarak, Fahmy A.
    INTERNATIONAL JOURNAL OF SURGERY OPEN, 2024, 62 (06) : 810 - 815
  • [9] Rhino-orbito-cerebral mucormycosis during Covid-19 pandemic- a prospective observational study
    Fatima, Nazish
    Ahmed, Shariq
    Shameem, Mohammad
    Ahmed, Aftab
    Hasan, Wasil
    Khan, Parvez A.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2023, 46
  • [10] A Study of Rhino-Orbito-Cerebral Mucormycosis with COVID-19: A New Challenge in North West of Rajasthan
    Kumar, Surendra
    Kumar, Harish
    Mali, Manoj
    Meena, Babu Lal
    ANNALS OF AFRICAN MEDICINE, 2022, 21 (04) : 383 - 389